APOE and chronic kidney disease: Our findings suggest that empagliflozin treatment may slow down kidney function decline and reduce serum phosphorus levels in 5/6 Nx ApoE−/− mice with VC induced by a high-phosphorus diet, implying that phosphate reduction in CKD could potentially offer beneficial effects in alleviating VC.